#array biopharma

Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings

Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings

Reporter: Stephen J. Williams, PhD

As reported in FiercePharma.com:

by Angus Liu |

Jun 17, 2019 11:42am

Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology.

In the first big M&A deal under new CEO Albert Bourla, Pfizer…

Array BioPharma reports Q3 2019 earnings results

Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019. The company reported a loss of 17 cents per share, compared to 21 cents expected by Wall Street.

Revenues for the quarter fell 2.5% to $64.7 million but were higher than the street view of $51.5 million.

Image for representation (Photo by Drew Hays on Unsplash)

ARRY shares have gained 55% so far…

Array BioPharma delivers strong Q2 results, investors cheer

Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million of milestone revenue from Loxo Oncology.  The topline came in well above street projection of $49.02 million.

Net loss was cut down to to 5 cents per share from 17 cents per share last year. Analysts were expecting loss of 16 cents per share.

ARRY…

Array BioPharma (ARRY:NAS) Fundamental Valuation Report

Fundamental Valuation Report

Array BioPharma(ARRY:NAS) Healthcare:Biotechnology

This Report was generated using…

Array BioPharma (ARRY:NAS) Fundamental Valuation Report

Fundamental Valuation Report

Array BioPharma(ARRY:NAS) Healthcare:Biotechnology

This Report was generated using…

Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma

January 18, 2018

Exelixis, Inc. and Ipsen have announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC) at the 2018 ASCO-GI…

Top Pharma News | July – August 2017

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

July 5, 2017

Bristol-Myers Squibb Company has announced that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection met its primary…

Top Pharma News of the Week

Amgen and Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation

July 18, 2017

Amgen and Array BioPharma have announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array’s proprietary platform that leverages Array’s expertise in chemistry…